On Invalid Date, Intra Cellular Therapies (NASDAQ: ITCI) reported Q4 2023 earnings per share (EPS) of -$0.30, up 34.78% year over year. Total Intra Cellular Therapies earnings for the quarter were -$28.58 million. In the same quarter last year, Intra Cellular Therapies's earnings per share (EPS) was -$0.46.
As of Q2 2024, Intra Cellular Therapies's earnings has grown year over year. Intra Cellular Therapies's earnings in the past year totalled -$139.67 million.
What is ITCI's earnings date?
Intra Cellular Therapies's earnings date is Invalid Date. Add ITCI to your watchlist to be reminded of ITCI's next earnings announcement.
What was ITCI's revenue last quarter?
On Invalid Date, Intra Cellular Therapies (NASDAQ: ITCI) reported Q4 2023 revenue of $132.10 million up 50.34% year over year. In the same quarter last year, Intra Cellular Therapies's revenue was $87.87 million.
What was ITCI's revenue growth in the past year?
As of Q2 2024, Intra Cellular Therapies's revenue has grown 85.51% year over year. This is 75.29 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.23%. Intra Cellular Therapies's revenue in the past year totalled $464.37 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.